Trial Profile
An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2015 Planned number of patients changed from 20 to 9 as reported by ClinicalTrials.gov
- 15 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov